The FDA granted accelerated approval to a new targeted therapy for certain patients with advanced or metastatic cholangiocarcinoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to futibatinib (Lytgobi) for adult...
The FDA granted accelerated approval to selpercatinib to treat solid tumors harboring RET gene fusions. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to selpercatinib (Retevmo) for the treatment of adult...
The FDA granted full approval to selpercatinib for the treatment of patients with advanced lung cancer. The U.S. Food and Drug Administration (FDA) has approved selpercatinib (Retevmo) for the treatment of patients with locally...
An inhibitor of the growth-stimulating FGFR1 protein was approved for patients with a rare type of blood cancer. The U.S. Food and Drug Administration (FDA) has approved pemigatinib (Pemazyre) for adult patients with relapsed...
The FDA granted accelerated approval to the first HER2-targeted therapy for the treatment of non-small cell lung cancer with activating HER2 mutations The U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
The FDA approved the kinase inhibitor capmatinib for lung cancers harboring a certain mutation in the protein MET. The U.S. Food and Drug Administration (FDA) has granted full approval to capmatinib (Tabrecta) for the...
The FDA approved a HER2-targeted therapy for the treatment of breast tumors with low HER2 expression. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of adult patients...
The FDA approved darolutamide for the treatment of metastatic prostate cancer that is sensitive to hormone-blocking treatment. The U.S. Food and Drug Administration (FDA) has approved darolutamide (Nubeqa), in combination with the chemotherapy docetaxel,...
The FDA approved a kinase inhibitor for the treatment of inflammatory myofibroblastic tumors in children and adults. The U.S. Food and Drug Administration has approved crizotinib (Xalkori) for the treatment of certain patients 1...
The CAR T-cell therapy lisocabtagene maraleucel was approved for the second-line treatment of certain patients with large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi) for the second-line...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More